ITEK Inotek Pharmaceuticals Corporat

1.63
+0.02  (1.56%)
Previous Close 1.60
Open 1.60
Price To book 0.51
Market Cap 43.76M
Shares 26,930,000
Volume 158,030
Short Ratio 1.27
Av. Daily Volume 1,023,420

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 initiated July 2016. Data due 2H 2017.
Trabodenoson and latanoprost
Glaucoma

Latest News

  1. INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  2. ITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017
  3. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  4. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017
  5. Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inotek Pharmaceuticals Corporation (ITEK) and Encourages Investors with Losses to Contact the Firm
  6. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  7. ITEK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017
  8. Inotek Pharmaceuticals to Present at the BIO CEO and Investor Conference
  9. INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  10. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline: March 7, 2017
  11. EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  12. Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Inotek Pharmaceuticals Corporation (ITEK) and Encourages Investors to Contact the Firm
  13. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  14. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017
  15. IMPORTANT INOTEK INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the District of Massachusetts against Inotek Pharmaceuticals Corporation
  16. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  17. ITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017
  18. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  19. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline: March 7, 2017
  20. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Inotek Pharmaceuticals Corporation To Contact The Firm Before Lead Plaintiff Deadline